- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02155244
Common Bile Duct Stone Management: What Have we Learned? (CBDS)
Study Overview
Status
Conditions
Detailed Description
The prevalence of gallstone disease increases with age, and as many as one third of women and one fifth of men over the age of 60 years have gallstones. The quoted prevalence of CBDS in patients with symptomatic gallstones varies, but probably lies between 10 and 20%. In Europe and Northern America 8 to 20% of cases of cholelithiasis is complicated by presence of common bile duct stones (CBDS) during cholecystectomy. When ductal stones do become symptomatic the consequences are often serious and can include pain, partial or complete biliary obstruction, cholangitis, hepatic abscesses or pancreatitis. Recent guidelines for the treatment of CBDS recommend that in patients with symptoms and clinical evaluation suggesting ductal stones as a cause, stones should be extracted if possible, except in selected patients that have contraindications (e.g high risks patients, refusal of endoscopic or operative treatment).
Many different approaches are currently being used for the management of bile duct calculi. These strategies differ considerably in terms of technical complexity, sensitivity, specificity, effectiveness, and cost. Where initial assessment suggests a high probability of CBDS, then it is reasonable to proceed directly to ERCP if this is considered the treatment of choice. Intraoperative cholangiography with selective intraoperative or postoperative ERCP is a strategy than routine preoperative ERCP, unless the presence of common bile duct stones (CBD) is almost certain. Current data does not suggest clear superiority of any one approach with regard success, mortality, morbidity and cost-effectiveness. In unfit elderly people with comorbid disease leaving the gallbladder in situ is justified after ERCP treatment. Cholangitis is more present in elderly people. Leaving the gallbladder in situ does not reduce the morbidity rate after ERCP for CBDS, especially in patients with cholangitis
All 101 patients with symptomatic and suspected CBD stones admitted to Surgical Department of "Ospedale Regionale di Mendrisio" from january 2006 to december 2013 were evaluated retrospectively for study eligibility. Patients were followed for the duration of hospital stay, the median hospital stay was 9 days.
From our Hospital informatic system, information on age, sex, length of hospital stay, and procedures undertaken during hospital admissions for patients with biliary diagnoses were retrieved. Initial patient evaluations consisted of history and physical examinations and serum analyses for inflammatory parameters, bilirubin, alkaline phosphatase, transaminase, and amylase. Previous history of jaundice or acute pancreatitis was recorded. In addition, right upper quadrant abdominal sonograms and CT scan were obtained for the determination of cholelithiasis and CBD diameter. The diagnosis of cholangitis was based on presence of clinical evidence of infection in patients with biliary obstruction in the form of jaundice or hyperbilirubinemia.
In our institution, patients with cholelithiasis, a CBD stones at US examination, and liver enzyme elevation, without clinical evidence of cholecystitis or biliary pancreatitis underwent ERCP, endoscopic sphincterotomy, and endoscopic clearance of CBD stones before laparoscopic cholecystectomy (LC). In patients with acute cholangitis, a dilated common bile duct on US, the first treatment was also ERCP. Patients with cholelithiasis, CBD and intrahepatic bile duct (IHBD) dilatation, and liver enzyme elevation, in the presence of cholecystitis, biliary pancreatitis, or apparent resolving symptomatic choledocholithiasis underwent further evaluation with magnetic resonance imaging(MR), and these patients underwent therapeutic ERCP when choledocholithiasis was demonstrated by MR, whereas patients whose MR did not detect choledocholithiasis underwent LC with intraoperative cholangiography (IOC). When we found CBD during LC, an ERCP was performed in the same operating time ("rendez-vous") or post operatively.
Endoscopic retrograde cholangiopancreatography(ERCP) with papillotomy was performed in patients with confirmed common bile duct stones(CBDS) by a single gastroenterologist.
In our Hospital, the procedure is performed in radiological room that contains x-ray equipment. We use a Olympus® duodenalendoscope TJF-145 for ERCP, Erbe® system for papillotomy diathermy, and Lithotriptor® if stone crushing is necessary. The patient is in prone position under general anesthesia. When performing endoscopic stone extraction the endoscopist has the support of a technician or radiologist who can assist in fluoroscopic screening and an additional endoscopy assistant/nurse to manage guide wires.
The relationship between ERCP and surgery was assessed by dividing the patients into 2 groups: patients who had ERCP without cholecystectomy (Group 1), patients who had ERCP + cholecystectomy (Group 2). Endpoint was to detect difference in age, indication (cholangitis and lithiasis), morbidity, effectiveness and success of CBD clearance in different groups.
Study Type
Enrollment (Actual)
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patients with common bile duct stones (CBDS)
Exclusion Criteria:
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Retrospective
Cohorts and Interventions
Group / Cohort |
|---|
|
Common bile duct stones
Common bile duct stones traeted with ERCP
|
|
CBDS
treated with ERCP combined with surgery
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Post-operative complications according to Clavien-Dindo classification
Time Frame: During patients hospitalization (median hospital stay was 9 days)
|
During patients hospitalization (median hospital stay was 9 days)
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- LR-1234
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Common Bile Duct Stones
-
Qilu Hospital of Shandong UniversityThe Affiliated Hospital of Qingdao University; Qingdao Municipal Hospital; Qianfoshan... and other collaboratorsRecruitingCholelithiasis Associated With Common Bile Duct StonesChina
-
Rija ZainabShaikh Zayed Hospital, LahoreRecruitingCholelithiasis Associated With Common Bile Duct StonesPakistan
-
Qilu Hospital of Shandong UniversityThe Affiliated Hospital of Qingdao University; Qingdao Municipal Hospital; Qianfoshan... and other collaboratorsRecruitingCholelithiasis Associated With Common Bile Duct StonesChina
-
Mohamed Ahmed Hassan AlyNot yet recruitingRecurrent Common Bile Duct StonesEgypt
-
Karolinska InstitutetCompletedCommon Bile Duct StonesSweden
-
Mansoura UniversityCompletedCommon Bile Duct Stones.Egypt
-
Air Force Military Medical University, ChinaCompletedCommon Bile Duct Gall Stones | Common Bile Duct GallStonesChina
-
Northwestern UniversityUniversity of Colorado, Denver; University of California, Los Angeles; University... and other collaboratorsWithdrawnCommon Bile Duct Stones | Bile Duct StricturesUnited States
-
Royal Brompton & Harefield NHS Foundation TrustCompletedCommon Bile Duct StonesUnited Kingdom